GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Niagen Bioscience Inc (NAS:NAGE) » Definitions » Price-to-Operating-Cash-Flow

NAGE (Niagen Bioscience) Price-to-Operating-Cash-Flow : 43.80 (As of May. 28, 2025)


View and export this data going back to 2008. Start your Free Trial

What is Niagen Bioscience Price-to-Operating-Cash-Flow?

As of today (2025-05-28), Niagen Bioscience's share price is $10.60. Niagen Bioscience's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2025 was $0.24. Hence, Niagen Bioscience's Price-to-Operating-Cash-Flow Ratio for today is 43.80.

The historical rank and industry rank for Niagen Bioscience's Price-to-Operating-Cash-Flow or its related term are showing as below:

NAGE' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 14.74   Med: 51.16   Max: 253.33
Current: 43.87

During the past 13 years, Niagen Bioscience's highest Price-to-Operating-Cash-Flow Ratio was 253.33. The lowest was 14.74. And the median was 51.16.

NAGE's Price-to-Operating-Cash-Flow is ranked worse than
67.75% of 307 companies
in the Biotechnology industry
Industry Median: 24.23 vs NAGE: 43.87

Niagen Bioscience's Cash Flow from Operations per share for the three months ended in Mar. 2025 was $0.10. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2025 was $0.24.

During the past 12 months, the average Operating Cash Flow per Share Growth Rate of Niagen Bioscience was 290.30% per year.

During the past 13 years, Niagen Bioscience's highest 3-Year average Operating Cash Flow per Share Growth Rate was 42.80% per year. The lowest was -187.30% per year. And the median was 4.10% per year.


Niagen Bioscience Price-to-Operating-Cash-Flow Historical Data

The historical data trend for Niagen Bioscience's Price-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Niagen Bioscience Price-to-Operating-Cash-Flow Chart

Niagen Bioscience Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Price-to-Operating-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 15.05 34.23

Niagen Bioscience Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Price-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 56.13 182.00 66.36 34.23 28.51

Competitive Comparison of Niagen Bioscience's Price-to-Operating-Cash-Flow

For the Biotechnology subindustry, Niagen Bioscience's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Niagen Bioscience's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Niagen Bioscience's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Niagen Bioscience's Price-to-Operating-Cash-Flow falls into.


;
;

Niagen Bioscience Price-to-Operating-Cash-Flow Calculation

Niagen Bioscience's Price-to-Operating-Cash-Flow ratio for today is calculated as

Price-to-Operating-Cash-Flow Ratio=Share Price/Cash Flow from Operations per share (TTM)
=10.60/0.242
=43.80

Niagen Bioscience's Share Price of today is $10.60.
Niagen Bioscience's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.24.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).

It can also be calculated from the numbers for the whole company:

Price-to-Operating-Cash-Flow Ratio=Market Cap/Cash Flow from Operations

Niagen Bioscience Price-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Niagen Bioscience's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Niagen Bioscience Business Description

Traded in Other Exchanges
Address
10900 Wilshire Boulevard, Suite 600, Los Angeles, CA, USA, 90024
Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.
Executives
Jaksch Frank L Jr director, 10 percent owner, officer: Chief Executive Officer 10005 MUIRLANDS BOULEVARD, SUITE G FIRST FLOOR, IRVINE CA 92618
Kristin Patrick director 3329 CAY DRIVE, SHERMAN OAKS CA 91423
Brianna Gerber officer: SVP Finance / Interim CFO C/O CHROMADEX, INC., 1735 FLIGHT WAY, SUITE 200, TUSTIN CA 92782
Champion River Ventures Ltd 10 percent owner C/O 7F, CHEUNG KONG CENTER, 2 QUEEN'S ROAD, CENTRAL K3 00000
Robert N Fried director 100 NORTH CRESCENT DRIVE, BEVERLY HILLS CA 90210
Steven D Rubin director OPKO HEALTH, INC., 4400 BISCAYNE BLVD., MIAMI FL 33137
Li Ka Shing 10 percent owner 79 DEEP WATER BAY ROAD, HONG KONG F4 00000
Chau Hoi Shuen Solina Holly 10 percent owner SUITES PT. 2909 & 2910, HARBOUR CENTRE, 25 HARBOUR ROAD, WANCHAI K3 999077
Hamed Shahbazi director C/O CHROMADEX, INC., 1735 FLIGHT WAY, SUITE 200, TUSTIN CA 92782
Ann Cohen director C/O CHROMADEX CORPORATION, 10900 WILSHIRE BLVD. STE 600, LOS ANGELES CA 90024
Ng Wang Yu Gary director ROOM 1709 HARBOUR CENTER, 25 HARBOUR ROAD, WANCHAI K3 -
Caroline S Levy director 2424 N FEDERAL HIGHWAY, SUITE 208, BOCA RATON FL 33431
Stephen A Block director INTERNATIONAL FLAVORS & FRAGRANCES INC., 521 WEST 57TH ST, NEW YORK NY 10019
Lisa Hatton Harrington officer: General Counsel 53 SEA TERRACE, NEWPORT COAST CA 92657
Kevin M Farr officer: Chief Financial Officer MATTEL, INC., 333 CONTINENTAL BLVD, M1-1518, EL SEGUNDO CA 90245